Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06104228 · ClinicalTrials.gov registry record · Phase 2
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
A Phase 2 study of Pulmonary Arterial Hypertension and Connective Tissue Diseases, sponsored by Bastiaan Driehuys.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06104228: Recruiting Phase 2 study of Pulmonary Arterial Hypertension and Connective Tissue Diseases, sponsored by Bastiaan Driehuys.
NCT06104228 is a Phase 2 study of Pulmonary Arterial Hypertension and Connective Tissue Diseases that is actively recruiting participants, run by Bastiaan Driehuys. The registered enrollment target is 20 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06104228, a Phase 2 study of Pulmonary Arterial Hypertension and Connective Tissue Diseases, is actively recruiting participants, sponsored by Bastiaan Driehuys.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).
Primary Outcome
The primary endpoint for this trial will be the change in defect + low percentage of RBC signal on hyperpolarized 129Xe MRI from baseline to 12 months
Conditions Studied
Interventions
- DRUG 129Xe Hyperpolarized
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-08-12 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
What NCT06104228 shows while recruiting
NCT06104228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which 129Xe Hyperpolarized is the first listed.
NCT06104228 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06104228 about?
NCT06104228 is a clinical study titled "129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)". The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additi...
What is the current status of trial NCT06104228?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-08-12. Estimated completion is 2027-03-31.
What conditions does trial NCT06104228 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension, Connective Tissue Diseases, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder).
What interventions are being tested in trial NCT06104228?
The interventions under investigation include: 129Xe Hyperpolarized (DRUG).
Who is sponsoring clinical trial NCT06104228?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06104228 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06104228's enrollment target sits among peer trials
20 49th of 63 higher than 10 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
Repurposing Valsartan May Protect Against Pulmonary Hypertension
RECRUITING · Phase 2
-
Spironolactone for Pulmonary Arterial Hypertension
RECRUITING · Phase 2
-
129 Xenon Imaging in Patients Treated With Sotatercept
RECRUITING · Phase 2
-
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI